Genentech and Roche initiated a phase 3 clinical trial to investigate the Port Delivery System with ranibizumab to treat patients with diabetic macular edema, according to a press release.
The Port Delivery System (PDS) is a refillable eye implant designed to continuously release a customized formulation of ranibizumab over a period of months.
“We are excited that patient enrollment in Pagoda has begun. This is the first clinical trial to investigate the PDS in DME, a serious retinal condition that affects nearly 750,000 people in the U.S. and is the (Read more...)
Uncategorized